Skip to main content
SP5007,674.37+0.43%DOW53,277.01+0.98%NASDAQ26,180.46+0.43%BTC$77,812.00+5.53%ETH$2,513.75+7.22%GOLD$4,661.60+1.97%OIL$86.64-0.22%
Smart Investors Daily
Sign InSign Up Free
TS

NASDAQ · TSHA

Taysha Gene Therapies, Inc.

Healthcare · Biotechnology

$6.09

Down-$0.02 (-0.33%)

Updated Aug 22, 2026, 2:42 AM

SID Score

6.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.51B
P/E ratio
-20.4
Dividend yield
0.00%
52-week range
$4.03 – $7.30
Volume
2.83M
Avg. volume
6.31M

Price performance

TSHA price history

1M range · 0 trading sessions · Daily adjusted prices

TSHA does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest TSHA news

The latest Smart Investors Daily articles mentioning TSHA.

Stock researchCompany · Overview

TSHA research

Overview

Company profile and research snapshot.

Company profile

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$10.83
Implied upside
—
Analysts
—
TSHA recent ratings
DateFirmRatingTarget
Jul 21, 2026Goldman SachsBuy—
Jul 2, 2026CitizensMarket Outperform—
Jun 30, 2026BairdOutperform—
Jun 30, 2026NeedhamBuy—
Jun 23, 2026BMO CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 13, 2026

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

Taysha Gene Therapies (TSHA) drew fresh investor attention after reporting a 100% overall response rate in early TSHA-102 Rett syndrome trial data, expanding its Catalent manufacturing agreement, and outlining cash coverage into late 2028. See our latest analysis for Taysha Gene Therapies. Taysha Gene Therapies has seen its share price move around these updates, with a 19.05% 30 day share price return and a very large 1 year total shareholder return, while the 5 year total shareholder return...

Yahoo · Aug 12, 2026

Taysha Gene Therapies Q2 Earnings Call Highlights

Taysha Gene Therapies (NASDAQ:TSHA) said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential biologics license application submission. Chief Executive Officer Sean Nolan said the company dosed 1

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By